Our core development programs are focused in the areas of pulmonology and hepatology. In pulmonology, we are developing therapies for the treatment of idiopathic pulmonary fibrosis. In hepatology, we are developing therapies focused on expanding treatment options for patients suffering from chronic hepatitis C.
For additional information on Actimmune® including full
prescribing information, please go to www.actimmune.com.
July 27, 2010
InterMune Reports Second Quarter 2010 Financial Results
July 20, 2010
InterMune to Release Second Quarter Financial Results on July 27